Evidence map›Paper›PMID 38962770›Full record

Observational studyFrontiers in public health2024

Profiling and assessing the risks of image- and performance-enhancing drugs use during the COVID-19 lockdown.

Ilaria De Luca, Francesco Di Carlo, Julius Burkauskas, Artemisa R Dores, Irene P Carvalho, M Ángeles Gómez-Martínez, Attila Szabo, Hironobu Fujiwara, Cristina Monteiro Barbosa, Marco Di Nicola and 11 more

Abstract readObservational Study
In one paragraph

Observational study in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Ilaria De Luca *Department of Clinical, Pharmaceutical and Biological Sciences, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom.
Francesco Di Carlo *Department of Neuroscience, Imaging, and Clinical Science, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.
Julius BurkauskasLaboratory of Behavioural Medicine, Neuroscience Institute, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Artemisa R DoresLaboratory of Neuropsychophysiology, Faculty of Psychology and Education Sciences, University of Porto, Porto, Portugal.
Irene P CarvalhoLaboratory of Neuropsychophysiology, Faculty of Psychology and Education Sciences, University of Porto, Porto, Portugal.
M Ángeles Gómez-MartínezDepartment of Psychology, Pontifical University of Salamanca, Salamanca, Spain.
Attila SzaboInstitute of Health Promotion and Sport Sciences, ELTE Eötvös Loránd University, Budapest, Hungary.
Hironobu FujiwaraDepartment of Neuropsychiatry, Graduate School of Medicine, University of Kyoto, Kyoto, Japan.
Cristina Monteiro BarbosaDepartment of Psychometrics, Institute of Psychology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Marco Di NicolaDepartment of Psychometrics, Institute of Psychology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Marianna MazzaDepartment of Geriatrics, Neuroscience and Orthopedics, Institute of Psychiatry and Psychology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
Gabriele SaniDepartment of Psychometrics, Institute of Psychology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Debora LucianiDepartment of Neuroscience, Imaging, and Clinical Science, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.
Mauro PettorrusoDepartment of Neuroscience, Imaging, and Clinical Science, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.
Massimo di GiannantonioDepartment of Neuroscience, Imaging, and Clinical Science, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.
Ilaria CataldoDepartment of Psychology and Cognitive Science, University of Trento, Trento, Italy.
Gianluca EspositoDepartment of Geriatrics, Neuroscience and Orthopedics, Institute of Psychiatry and Psychology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
Giovanni MartinottiDepartment of Clinical, Pharmaceutical and Biological Sciences, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom.
Thomas ZandonaiDepartment of Psychology and Cognitive Science, University of Trento, Trento, Italy.
Olivier RabinDepartment of Psychology and Cognitive Science, University of Trento, Trento, Italy.
Ornella CorazzaDepartment of Clinical, Pharmaceutical and Biological Sciences, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Image and Performance-Enhancing Drugs (IPEDs) can enhance mental and physical capabilities and impact one's overall health. Initially confined in sport environments, IPEDs use has become increasingly widespread in a high-performing society. The present study was aimed at profiling IPEDs use during the COVID-19 lockdown among an international sample of young adults. Methods: A cross-sectional observational study was carried out in eight countries (United Kingdom, Italy, Lithuania, Hungary, Portugal, Spain, Brazil, and Japan) between April and May 2020. The survey questionnaire included validated measurements such as Exercise Addiction Inventory (EAI), Appearance Anxiety Inventory (AAI), and Self-Compassion Scale (SCS) as well as questions about the type of IPEDs, purchasing methods and socio-demographic information. Results: A total of 736 IPEDs users were included in the survey. Their mean age was 33.05 years (± Conclusion: This study profiled users of IPEDs when the most restrictive COVID-19 lockdown policies were implemented in all the participating countries. More targeted post-COVID 19 prevention strategies should be implemented according to the emerged socio-demographic and psychopathological traits and cross-cultural differences emerged. Longitudinal studies will also be needed to determine the long-term effect of the COVID-19 lockdown on IPEDs consumption.

Indexed as

COVID-19Performance-Enhancing SubstancesAdultBehavior, AddictiveCross-Sectional StudiesExerciseFemaleHumansMaleSARS-CoV-2Substance-Related DisordersSurveys and QuestionnairesYoung AdultPerformance-Enhancing Substancesbody imageCOVID-19exercise addictionexercise dependenceimage and performance enhancing drugspandemic

Identifiers

PMID38962770
PMCPMC11221326

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.